Share Prices & Company Research

Market News

26 Nov 2018 | 13:56

NetScientific portfolio company PDS Biotechnology merges with Edge Therapeutics

NetScientific said portfolio company PDS Biotechnology Corporation had agreed to merge with Edge Therapeutics.

The all-share merger was expected to create a combined company with a 'robust pipeline of next generation cancer immunotherapies' with sufficient cash to fund operations into 2020, NetScientific said.

It would operate under the PDS Biotechnology name.

'We are delighted that the board of Edge has selected PDS after a rigorous selection process, as we believe this provides further important validation of the Versamune technology platform,' chief executive Francois R. Martelet said.

At 1:56pm: (LON:NSCI) Netscientific Plc share price was +0.5p at 27p

Story provided by
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.